![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF626 |
Gene summary for ZNF626 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF626 | Gene ID | 199777 |
Gene name | zinc finger protein 626 | |
Gene Alias | ZNF626 | |
Cytomap | 19p12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q68DY1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
199777 | ZNF626 | HCC1_Meng | Human | Liver | HCC | 1.67e-57 | 6.86e-02 | 0.0246 |
199777 | ZNF626 | cirrhotic2 | Human | Liver | Cirrhotic | 1.31e-02 | 5.21e-02 | 0.0201 |
199777 | ZNF626 | HCC1 | Human | Liver | HCC | 2.83e-04 | 7.34e-01 | 0.5336 |
199777 | ZNF626 | HCC2 | Human | Liver | HCC | 8.57e-25 | 2.82e+00 | 0.5341 |
199777 | ZNF626 | HCC5 | Human | Liver | HCC | 7.60e-15 | 1.21e+00 | 0.4932 |
199777 | ZNF626 | S014 | Human | Liver | HCC | 2.15e-02 | 1.95e-01 | 0.2254 |
199777 | ZNF626 | male-WTA | Human | Thyroid | PTC | 2.86e-15 | 1.04e-01 | 0.1037 |
199777 | ZNF626 | PTC01 | Human | Thyroid | PTC | 3.34e-12 | 1.51e-01 | 0.1899 |
199777 | ZNF626 | PTC04 | Human | Thyroid | PTC | 9.19e-13 | 2.15e-01 | 0.1927 |
199777 | ZNF626 | PTC05 | Human | Thyroid | PTC | 2.43e-15 | 5.48e-01 | 0.2065 |
199777 | ZNF626 | PTC06 | Human | Thyroid | PTC | 6.99e-21 | 5.25e-01 | 0.2057 |
199777 | ZNF626 | PTC07 | Human | Thyroid | PTC | 3.64e-32 | 4.22e-01 | 0.2044 |
199777 | ZNF626 | ATC12 | Human | Thyroid | ATC | 3.82e-05 | -4.63e-02 | 0.34 |
199777 | ZNF626 | ATC13 | Human | Thyroid | ATC | 1.93e-23 | 3.48e-01 | 0.34 |
199777 | ZNF626 | ATC4 | Human | Thyroid | ATC | 7.99e-07 | -4.61e-03 | 0.34 |
199777 | ZNF626 | ATC5 | Human | Thyroid | ATC | 1.05e-22 | 3.93e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF626 | SNV | Missense_Mutation | novel | c.704N>T | p.Gly235Val | p.G235V | Q68DY1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ZNF626 | SNV | Missense_Mutation | c.974C>A | p.Ser325Tyr | p.S325Y | Q68DY1 | protein_coding | tolerated(0.22) | possibly_damaging(0.783) | TCGA-MP-A4TA-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF626 | SNV | Missense_Mutation | c.969G>T | p.Lys323Asn | p.K323N | Q68DY1 | protein_coding | tolerated(1) | benign(0.006) | TCGA-18-5592-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF626 | SNV | Missense_Mutation | c.725N>T | p.Ser242Phe | p.S242F | Q68DY1 | protein_coding | deleterious(0.01) | probably_damaging(0.916) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
ZNF626 | SNV | Missense_Mutation | c.1285G>A | p.Glu429Lys | p.E429K | Q68DY1 | protein_coding | tolerated(0.06) | benign(0.332) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF626 | SNV | Missense_Mutation | c.85T>C | p.Tyr29His | p.Y29H | Q68DY1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-43-6771-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF626 | SNV | Missense_Mutation | novel | c.1160A>G | p.His387Arg | p.H387R | Q68DY1 | protein_coding | deleterious(0) | possibly_damaging(0.756) | TCGA-52-7812-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | paclitaxel | PD |
ZNF626 | SNV | Missense_Mutation | c.1450N>A | p.Glu484Lys | p.E484K | Q68DY1 | protein_coding | tolerated(0.1) | benign(0.344) | TCGA-66-2766-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ZNF626 | SNV | Missense_Mutation | c.999N>T | p.Arg333Ser | p.R333S | Q68DY1 | protein_coding | tolerated(0.22) | possibly_damaging(0.575) | TCGA-66-2766-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ZNF626 | SNV | Missense_Mutation | novel | c.818N>C | p.Ser273Thr | p.S273T | Q68DY1 | protein_coding | tolerated(1) | benign(0.006) | TCGA-68-8251-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |